UPB - Upstream Bio, Inc.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts.

52W High

$29.46

52W Low

$5.14

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

251.40

P/S (TTM) (<3 favorable)

395.36

P/B (<3 favorable)

2.63

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

14.81%

Institutions (25–75% balanced)

90.42%

Shares Outstanding

53,909,000

Float

31,417,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

2,723,000

Gross Profit (TTM)

2,723,000

EPS (TTM)

-6.18

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-47.33%

ROE (TTM) (>15% strong)

-0.33%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.84

Momentum

Bearish momentum

Value

0.7809

0.9343

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025